Dual targeting CB1R/PPAR as well as co-administration have been reported as beneficial pharmacological strategies in the course of numerous pathologies including obesity, arthritis, cancer, epilepsy, and alcohol use disorder [31,41,42]. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.